Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes

MG Schouwenburg, A Jochems, Brenda Leeneman, Margreet Franken, AJM Van den Eertwegh, J Haanen, MCT van Zeijl, MJ Aarts, ACJ Akkooi, F van den Berkmortel, WAM Blokx, JWB de Groot, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MWJ Louwman, D Piersma, RS van Rijn, KPM SuijkerbuijkAJ ten Tije, G Vreugdenhil, M Wouters, JJM van der Hoeven

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)326-332
Number of pages7
JournalMelanoma Research
Volume28
Issue number4
DOIs
Publication statusPublished - 2018

Research programs

  • EMC NIHES-05-63-02 Quality
  • EMC MM-03-86-08

Cite this